159 related articles for article (PubMed ID: 34205025)
1. Possible Therapeutic Potential of Disulfiram for Multiple Myeloma.
Weiser Drozdkova D; Smesny Trtkova K
Curr Oncol; 2021 Jun; 28(3):2087-2096. PubMed ID: 34205025
[TBL] [Abstract][Full Text] [Related]
2. Disulfiram/copper markedly induced myeloma cell apoptosis through activation of JNK and intrinsic and extrinsic apoptosis pathways.
Xu Y; Zhou Q; Feng X; Dai Y; Jiang Y; Jiang W; Liu X; Xing X; Wang Y; Ni Y; Zheng C
Biomed Pharmacother; 2020 Jun; 126():110048. PubMed ID: 32145587
[TBL] [Abstract][Full Text] [Related]
3. Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies.
Conticello C; Martinetti D; Adamo L; Buccheri S; Giuffrida R; Parrinello N; Lombardo L; Anastasi G; Amato G; Cavalli M; Chiarenza A; De Maria R; Giustolisi R; Gulisano M; Di Raimondo F
Int J Cancer; 2012 Nov; 131(9):2197-203. PubMed ID: 22322883
[TBL] [Abstract][Full Text] [Related]
4. Disulfiram/copper targets stem cell-like ALDH
Jin N; Zhu X; Cheng F; Zhang L
J Cell Biochem; 2018 Aug; 119(8):6882-6893. PubMed ID: 29665144
[TBL] [Abstract][Full Text] [Related]
5. Targeting ALDH1A1 by disulfiram/copper complex inhibits non-small cell lung cancer recurrence driven by ALDH-positive cancer stem cells.
Liu X; Wang L; Cui W; Yuan X; Lin L; Cao Q; Wang N; Li Y; Guo W; Zhang X; Wu C; Yang J
Oncotarget; 2016 Sep; 7(36):58516-58530. PubMed ID: 27542268
[TBL] [Abstract][Full Text] [Related]
6. Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines.
Jivan R; Damelin LH; Birkhead M; Rousseau AL; Veale RB; Mavri-Damelin D
J Cell Biochem; 2015 Oct; 116(10):2334-43. PubMed ID: 25846272
[TBL] [Abstract][Full Text] [Related]
7. Disulfiram/copper causes ROS levels alteration, cell cycle inhibition, and apoptosis in acute myeloid leukaemia cell lines with modulation in the expression of related genes.
Hassani S; Ghaffari P; Chahardouli B; Alimoghaddam K; Ghavamzadeh A; Alizadeh S; Ghaffari SH
Biomed Pharmacother; 2018 Mar; 99():561-569. PubMed ID: 29902866
[TBL] [Abstract][Full Text] [Related]
8. Anti-cancer effects of disulfiram in head and neck squamous cell carcinoma via autophagic cell death.
Park YM; Go YY; Shin SH; Cho JG; Woo JS; Song JJ
PLoS One; 2018; 13(9):e0203069. PubMed ID: 30212479
[TBL] [Abstract][Full Text] [Related]
9. Process of immunogenic cell death caused by disulfiram as the anti-colorectal cancer candidate.
You SY; Rui W; Chen ST; Chen HC; Liu XW; Huang J; Chen HY
Biochem Biophys Res Commun; 2019 Jun; 513(4):891-897. PubMed ID: 31003768
[TBL] [Abstract][Full Text] [Related]
10. Targeting genotoxic and proteotoxic stress-response pathways in human prostate cancer by clinically available PARP inhibitors, vorinostat and disulfiram.
Majera D; Skrott Z; Bouchal J; Bartkova J; Simkova D; Gachechiladze M; Steigerova J; Kurfurstova D; Gursky J; Korinkova G; Cwiertka K; Hodny Z; Mistrik M; Bartek J
Prostate; 2019 Mar; 79(4):352-362. PubMed ID: 30499118
[TBL] [Abstract][Full Text] [Related]
11. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity.
Chen D; Cui QC; Yang H; Dou QP
Cancer Res; 2006 Nov; 66(21):10425-33. PubMed ID: 17079463
[TBL] [Abstract][Full Text] [Related]
12. Suppressing autophagy enhances disulfiram/copper-induced apoptosis in non-small cell lung cancer.
Wu X; Xue X; Wang L; Wang W; Han J; Sun X; Zhang H; Liu Y; Che X; Yang J; Wu C
Eur J Pharmacol; 2018 May; 827():1-12. PubMed ID: 29547841
[TBL] [Abstract][Full Text] [Related]
13. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer.
Allensworth JL; Evans MK; Bertucci F; Aldrich AJ; Festa RA; Finetti P; Ueno NT; Safi R; McDonnell DP; Thiele DJ; Van Laere S; Devi GR
Mol Oncol; 2015 Jun; 9(6):1155-68. PubMed ID: 25769405
[TBL] [Abstract][Full Text] [Related]
14. Disulfiram anti-cancer efficacy without copper overload is enhanced by extracellular H2O2 generation: antagonism by tetrathiomolybdate.
Calderon-Aparicio A; Strasberg-Rieber M; Rieber M
Oncotarget; 2015 Oct; 6(30):29771-81. PubMed ID: 26356671
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of disulfiram/copper complex in the poorly-differentiated nasopharyngeal carcinoma cells via activating ClC-3 chloride channel.
Xu X; Xu J; Zhao C; Hou X; Li M; Wang L; Chen L; Chen Y; Zhu L; Yang H
Biomed Pharmacother; 2019 Dec; 120():109529. PubMed ID: 31606620
[TBL] [Abstract][Full Text] [Related]
16. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
[TBL] [Abstract][Full Text] [Related]
17. Cancer Pro-oxidant Therapy Through Copper Redox Cycling:
Rieber M
Curr Pharm Des; 2020; 26(35):4461-4466. PubMed ID: 32600223
[TBL] [Abstract][Full Text] [Related]
18. Disulfiram when Combined with Copper Enhances the Therapeutic Effects of Temozolomide for the Treatment of Glioblastoma.
Lun X; Wells JC; Grinshtein N; King JC; Hao X; Dang NH; Wang X; Aman A; Uehling D; Datti A; Wrana JL; Easaw JC; Luchman A; Weiss S; Cairncross JG; Kaplan DR; Robbins SM; Senger DL
Clin Cancer Res; 2016 Aug; 22(15):3860-75. PubMed ID: 27006494
[TBL] [Abstract][Full Text] [Related]
19. Disulfiram combined with copper inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma through the NF-κB and TGF-β pathways.
Li Y; Wang LH; Zhang HT; Wang YT; Liu S; Zhou WL; Yuan XZ; Li TY; Wu CF; Yang JY
J Cell Mol Med; 2018 Jan; 22(1):439-451. PubMed ID: 29148232
[TBL] [Abstract][Full Text] [Related]
20. A Copper-Mediated Disulfiram-Loaded pH-Triggered PEG-Shedding TAT Peptide-Modified Lipid Nanocapsules for Use in Tumor Therapy.
Zhang L; Tian B; Li Y; Lei T; Meng J; Yang L; Zhang Y; Chen F; Zhang H; Xu H; Zhang Y; Tang X
ACS Appl Mater Interfaces; 2015 Nov; 7(45):25147-61. PubMed ID: 26501354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
